% | $
Quotes you view appear here for quick access.

Chimera Investment Corporation Message Board

darswan27 7 posts  |  Last Activity: May 13, 2016 12:59 PM Member since: Feb 7, 2010
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • darswan27 darswan27 May 13, 2016 12:59 PM Flag

    Looks like the market is not interested in a bottom yet. Still above average volume as investors simply want out . Vonage management has not made the case that Nexmo is a good acquisition. In fact their total silence is deafening.

  • darswan27 by darswan27 May 10, 2016 3:38 PM Flag

    My new book is entitled "Vonage for Dummies" Here's a quick peek at Chapter 1: "Acquisitions are Good for You." It is a well known fact that investors love acquisitions so at Vonage they are making sure everyone gets a double helping. It is not wise to digest the 2014 plate of acquisitions to show investors that management knows what it is doing and it's acquisitions are in fact accretive to earnings. No that's the old fashioned way. At Vonage it's best to throw a "Hail Mary" to see if No. 11 (remember 1 + 1= 11) can catch the ball for a touchdown! Don't ever forget these are smart folks and what's a 40% drop in shareholder value when you can "go for the fences" just like old Babe Ruth. The old Babe used to say "Never let the fear of striking out get in your way". stay tuned for Chapter 2.

  • Reply to

    Vonage Shows You How Not to Announce an Acquisition

    by oilggam May 6, 2016 10:54 AM
    darswan27 darswan27 May 6, 2016 2:53 PM Flag

    Management has been poorly advised. At the time of the announcement financials on Nexmo should have been made available. It doesn't matter if it was a private company they should have been generated as if Nexmo was doing an IPO. As I have said before the analyst community is skeptical of VG management and will need proof of value before they will give their stamp of approval on the deal. VG needs to quickly set up an analyst day and lay out the Nexmo financials, the basis for synergy savings and the marketing case why 1 plus 1 = 11 as management so famously said. Investors in public companies always have the right to sue the Board of Directors and the Company if they believe the Board has violated it's fiduciary responsibility. Is a 20% drop in value enough to trigger lawsuits? Maybe not but I would think if VG loses more than 30% of it's pre announcement value the lawyers will begin to circle.

  • Reply to

    Longs licking their wounds

    by jake_samuals May 5, 2016 1:36 PM
    darswan27 darswan27 May 5, 2016 3:39 PM Flag

    Agree. But it may take a quarter or 2 to convince analyst community that this was a smart play. Remember management raised guidance AND held EBITDA. Sorry but the analysts don't like/trust management. Not one positive note or comment that I can find on the acquisition. Maybe someone will get on board and tell their clients VG is a screaming buy at this level and we will see a pop above $4.50. But a breakout to the upside doesn't seem to be in the cards now.

    Sentiment: Buy

  • Reply to

    Longs licking their wounds

    by jake_samuals May 5, 2016 1:36 PM
    darswan27 darswan27 May 5, 2016 2:34 PM Flag

    simple. A) Analysts think they overpaid for $125 mil in revenue and don't like the cash drain from the credit facility plus paying partially in stock. B. Worried about how long it will it take management to leverage the new asset to be accretive to earnings. Conclusion: sell and reinvest proceeds in a less risky play. You may agree or disagree but the hot money is moving on.

  • darswan27 darswan27 Feb 16, 2016 12:00 PM Flag

    "Heaven has no rage like love to hatred turned, Nor hell a fury like a woman scorned" William Congreve in The Mourning Bride. 1697

  • Reply to

    NYSE Listing

    by yankel222 Jan 11, 2016 10:03 AM
    darswan27 darswan27 Jan 11, 2016 11:54 AM Flag

    With no buyers momentum building to find a stategic partner and take the company private. Small premium to current price to ward off law suits .

16.14-0.09(-0.55%)Sep 29 4:01 PMEDT